VRTX - Arcturus: H1 2024 Rare Disease Drug Data On Deck
2024-01-31 17:20:05 ET
Summary
- Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024.
- The global Cystic Fibrosis market is projected to grow to $12.9 billion by 2030.
- Interim results from the phase 2 study, using ARCT-810 for the treatment of patients with OTC Deficiency, are expected in the 1st half of 2024.
- Received approval with partner CSL in Japan for ARCT-154 as the first self-amplifying mRNA vaccine for adults with COVID-19.
Arcturus Therapeutics Holdings Inc. ( ARCT ) is gearing up to report results from its phase 1b study using its inhaled messenger RNA [mRNA] treatment known as ARCT-032 for the treatment of patients with Cystic Fibrosis [CF]. There is an important catalyst to watch with respect to this program, which is that there will be the release of interim results from this phase 1b study in the 1st half of 2024....
Arcturus: H1 2024 Rare Disease Drug Data On Deck